Global Scientific Publications At ESTEVE, we make an effort to broadcast the discoveries we make in high-ranking peer-reviewed scientific journals. Below you will find the list with the latest works that we have published. Publications • Co-crystals as a new approach to multimodal analgesia and the treatment of pain. Journal of pain research. 2019, 12: 2679-2689 • Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms. Frontiers in pharmacology. 2019, 10(art.613): 1-16 • Blockade of the sigma-1 receptor relieves cognitive and emotional impairments associated to chronic osteoarthritis pain. Frontiers in pharmacology. 2019, 10(Art.468): 1-15 • Repeated sigma-1 receptor antagonist MR309 administration modulates central neuropathic pain development after spinal cord injury in mice. Frontiers in pharmacology. 2019, 10(Art.222): 1-14 • Pharmacokinetics of tramadol and celecoxib in Japanese and Caucasian subjects following administration of co-crystal of tramadol-celecoxib (CTC): A randomised, open-label study. European journal of drug metabolism and pharmacokinetics. 2019, 44(1): 63-75 • Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert opinion on investigational drugs. 2019, 28(5): 399-409 •Patrones de prescripcion de farmacos antihiperglucemiantes en pacientes ancianos en Espana: un estudio transversal nacional = Prescription patterns of antihyperglycemic drugs in elderly patients in Spain: A national cross-sectional study. Revista clínica española. 2019, Epub ahead of print: 1-7 • Synthesis and structure-affinity relationships of spirocyclic benzopyrans with exocyclic amino moiety. Journal of medicinal chemistry. 2019, 62(8): 4204-4217 • Modulation by Sigma-1 Receptor of Morphine Analgesia and Tolerance: Nociceptive Pain, Tactile Allodynia and Grip Strength Deficits During Joint Inflammation. Frontiers in pharmacology. 2019, 10(art.136): 1-16 • May a sigma-1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats? European journal of pain. 2019, 23(3): 603-620 • A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset. Frontiers in pharmacology. 2019, 10(Art.519): 1-16 • Differential Solution Behavior of the New API-API Co-Crystal of Tramadol-Celecoxib (CTC) versus Its Constituents and Their Combination. Crystal growth and design. 2019, Epub ahead of print: 1-11 • Trends in sigma-1 receptor research: a 25-year bibliometric analysis. Frontiers in pharmacology. 2019, 10(Art.564): 1-17 • Influence of the acid-base ionization of drugs in their retention in reversed-phase liquid chromatography. Analytica chimica acta. 2019, 200-211 • Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and 1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity. European journal of medicinal chemistry. 2019, 177: 47-62 • Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists. Journal of labelled compounds and radiopharmaceuticals. 2019, Epub ahead of print: 1-68 • Supraspinal and peripheral, but not intrathecal, 1R blockade by S1RA enhances morphine antinociception. Frontiers in pharmacology. 2019, 10(art.422): 1-13 • Commentary on the "Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial". Implications for cardiovascular safety. Journal of cardiology and cardiovascular sciences. 2019, 3(1): 1-3 Get to know our therapeutic areas Read more About us Who we are Corporate governance Our global presence Our commitment Therapeutic areas Contract Manufacturing R&D Research Areas Pipeline Scientific publications Patients B2B Partnering Media Corporate resources Contact Adverse reactions Work with us Privacy Legal notice Cookies policy Last update 11/11/2021 | © 1996-2021 ESTEVE Use of cookies We use our own and third-party cookies for analytic, technical and profiling purposes; we process data that is needed to create profiles based on your browsing habits. Press the "ACCEPT COOKIES" button to confirm their use. You can change the configuration of your cookies by pressing "MORE INFORMATION AND CONFIGURATION". ACCEPT COOKIES MORE INFORMATION AND CONFIGURATION * *This option allows you to reject the cookies.